| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2015 | US20150031634 Angiotensin peptides in treating marfan syndrome and related disorders |
| 01/29/2015 | US20150031628 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| 01/29/2015 | US20150031614 Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| 01/29/2015 | US20150031613 Methods and compositions comprising desmopressin in combination wtih a beta-3-adrenergic receptor agonist |
| 01/29/2015 | US20150031610 Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins |
| 01/29/2015 | US20150031544 Dry glassy composition comprising a bioactive material |
| 01/29/2015 | US20150031543 Compositions for aerosolization of highly conductive solutions |
| 01/29/2015 | US20150031127 Self-assembled nanostructures |
| 01/29/2015 | US20150030704 Pyridazinone compounds and their use as daao inhibitors |
| 01/29/2015 | US20150030701 Antimicrobial compositions and methods |
| 01/29/2015 | US20150030700 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs |
| 01/29/2015 | US20150030699 Anti-tumor adjuvant therapy |
| 01/29/2015 | US20150030698 Powdered drink mix for recovery |
| 01/29/2015 | US20150030693 Anti-tumor aqueous solution, anti-cancer agent, and methods for producing said aqueous solution and said anti-cancer agent |
| 01/29/2015 | US20150030690 Prebiotic mixture |
| 01/29/2015 | US20150030685 Sugar-Free Oral Transmucosal Fentanyl Citrate Lozenge Dosage Forms |
| 01/29/2015 | US20150030683 Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions |
| 01/29/2015 | US20150030680 Oral pharmaceutical compositions of dabigatran etexilate |
| 01/29/2015 | US20150030677 Tamper Resistant Immediate Release Formulations |
| 01/29/2015 | US20150030676 Stablized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
| 01/29/2015 | US20150030675 Controlled Release Dosage Forms |
| 01/29/2015 | US20150030674 Composition for polyunsaturated fatty acids encapsulation and process of preparation |
| 01/29/2015 | US20150030672 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| 01/29/2015 | US20150030671 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
| 01/29/2015 | US20150030668 Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions |
| 01/29/2015 | US20150030667 Compositions and methods for treating underactive bladder |
| 01/29/2015 | US20150030666 Adhesive skin patch |
| 01/29/2015 | US20150030665 Composition and Method for Treating Connective Tissue Damage |
| 01/29/2015 | US20150030654 PDLLA Stent Coating |
| 01/29/2015 | US20150030653 Vanadium Compounds as Therapeutic Adjuncts for Cartilage Injury and Repair |
| 01/29/2015 | US20150030652 Block copolymers of acrylates and methacrylates with fluoroalkenes |
| 01/29/2015 | US20150030638 Ingenol Derivatives in the Reactivation of Latent HIV |
| 01/29/2015 | US20150030626 Immunomodulatory conjugates |
| 01/29/2015 | US20150030620 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 01/29/2015 | US20150030618 Novel binder-drug conjugates (adcs) and use thereof |
| 01/29/2015 | US20150030616 Novel benzodiazepine derivatives |
| 01/29/2015 | US20150030610 Increasing taxane sensitivity in cancer cells |
| 01/29/2015 | US20150030605 Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
| 01/29/2015 | US20150030593 Compositions of penetration-enhanced targeting proteins and methods of use |
| 01/29/2015 | US20150030588 Combination of kinase inhibitors and uses thereof |
| 01/29/2015 | US20150030587 Human papilloma virus as predictor of cancer prognosis |
| 01/29/2015 | US20150030585 Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| 01/29/2015 | US20150030583 Methods of Treating Serosal Cancer |
| 01/29/2015 | US20150030579 Hydroxytyrosol combinations for enhancing mitochondrial function and energy production |
| 01/29/2015 | US20150030563 Compound for the Treatment of Enteroviruses |
| 01/29/2015 | US20150030561 Use of CXCR4 Antagonists |
| 01/29/2015 | US20150030560 Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| 01/29/2015 | US20150030559 Compositions and methods for treating and preventing skeletal muscle deficiencies |
| 01/29/2015 | US20150030551 Benzopyran compounds as melanogenesis modifiers and uses thereof |
| 01/29/2015 | US20150030550 Composition containing at least one c7 sugar for alopecia treatment, cosmetic treatment of hair and nails, and care of hair, eyelashes or nails |
| 01/29/2015 | US20150030549 Topical compositions |
| 01/29/2015 | US20150030543 Formulas for Diagnosing and Treating Hormone-Dependent Cancers and Cancers of the Organs Responsible for Steroid Hormone Synthesis |
| 01/29/2015 | US20150030537 Chlorotoxin polypeptides and conjugates and uses thereof |
| 01/29/2015 | US20150028512 Tamper resistant dosage forms |
| 01/29/2015 | US20150028503 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| 01/29/2015 | US20150027050 Coating metal oxide particles |
| 01/29/2015 | DE112013002484T5 Pteridinketon-Derivat und Anwendungen desselben als EGFR-, BLK- und FLT3-Inhibitor Pteridinketon derivative and applications thereof as EGFR, PFC and FLT3 inhibitor |
| 01/29/2015 | DE112013002074T5 Systeme und Methoden zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion Systems and methods for the treatment of opioid-induced adverse pharmacodynamic response |
| 01/29/2015 | DE102013012494A1 Verwendung von ß-Hydroxybuttersäure und Acetessigsäure sowie ihrer Salze (ß-Hydroxybutyrat und Acetacetat) als Mittel zur Behandlung bei erworbener Hypoglycorrhachie in Folge von Meningitis, Encephalitis oder Blutung in die Liquorräume Use of beta-hydroxybutyric acid and acetoacetic acid and its salts (beta-hydroxybutyrate and acetoacetate) as a means for the treatment of acquired Hypoglycorrhachie as a result of meningitis, encephalitis or bleeding in the subarachnoid spaces |
| 01/28/2015 | EP2829611A1 Sulfur amino acid-containing composition |
| 01/28/2015 | EP2829547A1 Sodium hydroxysafflor yellow a and production method and pharmaceutical use thereof |
| 01/28/2015 | EP2829545A1 New phosphate derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/28/2015 | EP2829539A1 New pyrrole derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/28/2015 | EP2829538A1 Polymorphic form of imatinib mesylate and process for its preparation |
| 01/28/2015 | EP2829536A1 4-Nitro-5-dichloromethylpyrazol derivatives for the treatment of infectious diseases |
| 01/28/2015 | EP2829284A1 Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor |
| 01/28/2015 | EP2829277A1 Use of a-type proanthocyanidins in treating a mineralocorticoid receptor related disease |
| 01/28/2015 | EP2829273A1 Method for producing liposome encapsulating paclitaxel monoglycoside and/or docetaxel monoglycoside |
| 01/28/2015 | EP2829272A1 Transdermal absorption preparation |
| 01/28/2015 | EP2829271A2 Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol and a further antidiabetic agent |
| 01/28/2015 | EP2829270A1 Joint product containing synephrine and topiramate |
| 01/28/2015 | EP2829269A1 Orally Disintegrating Tablet Formulation Comprising Flurbiprofen |
| 01/28/2015 | EP2829268A1 Compound formulations of 2-amino-1,3-propanediol compounds |
| 01/28/2015 | EP2829267A1 Topiramate sustained-release pharmaceutical composition, method for preparing same, and use thereof |
| 01/28/2015 | EP2829266A1 Joint product containing phentermine and topiramate and preparation method therefor |
| 01/28/2015 | EP2829265A2 Novel formulations for treatment of migraine |
| 01/28/2015 | EP2828387A1 Novel therapeutic target for the prevention of tumour metastasis |
| 01/28/2015 | EP2828332A1 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo |
| 01/28/2015 | EP2828277A1 Solid forms of a thiophosphoramidate nucleotide prodrug |
| 01/28/2015 | EP2828269A1 BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF PI3K-alpha AND/OR beta |
| 01/28/2015 | EP2828267A2 TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES |
| 01/28/2015 | EP2828263A1 Synthesis of polycyclic alkaloids and their use as tgr5 agonists |
| 01/28/2015 | EP2828262A1 Imidazotriazinone compounds |
| 01/28/2015 | EP2828261A1 Crystalline form of a succinate salt |
| 01/28/2015 | EP2828259A1 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
| 01/28/2015 | EP2828258A1 Novelpyridopyrimidine derivatives and use thereof |
| 01/28/2015 | EP2828257A1 Antibacterial compounds |
| 01/28/2015 | EP2828253A1 Carbamate compounds and of making and using same |
| 01/28/2015 | EP2828251A1 An improved process for the preparation of sunitinib and its acid addition salts thereof |
| 01/28/2015 | EP2828250A1 Quinazoline compounds and their use in therapy |
| 01/28/2015 | EP2828249A1 Premature-termination-codons readthrough compounds |
| 01/28/2015 | EP2828248A1 Flavone derivatives and their use |
| 01/28/2015 | EP2828247A1 Compounds for treating spinal muscular atrophy |
| 01/28/2015 | EP2828245A1 Antimicrobial agents |
| 01/28/2015 | EP2828244A1 Triazines with suitable spacers for treatment and/or prevention of hiv infections |
| 01/28/2015 | EP2828243A1 Estrogen receptor modulators and uses thereof |
| 01/28/2015 | EP2828242A1 NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. |
| 01/28/2015 | EP2828238A1 Sulphonamide derivatives of benzylamine for the treatment of cns diseases |
| 01/28/2015 | EP2827953A2 Compositions for delivering perfume to the skin |
| 01/28/2015 | EP2827904A1 Compounds and methods for kinase modulation, and indications therefor |